Serum Antinuclear Antibodies as Indicator of Relapse in Patients with Non-
Manal Mohamed Saber*
Department of Clinical Pathology, Faculty of Medicine- El- Minia University, Egypt
- *Corresponding Author:
- Manal Mohamed Saber
Department of Clinical Pathology
Faculty of Medicine- El- Minia University
E-mail: [email protected]
Received date: July 07, 2016; Accepted date: September 24, 2016; Published date:September 30, 2016
Citation: Saber MM (2016) Serum Antinuclear Antibodies as Indicator of Relapse in Patients with Non-Hodgkin’s Lymphoma. J Clin Cell Immunol 7:459. doi: 10.4172/2155-9899.1000459
Copyright: © 2016 Saber MM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The association of antinuclear antibodies (ANA) has been reported in Non-Hodgkin’s lymphoma (NHL). This study was conducted to assess the serum levels of ANA in NHL patients and its relationships with prognosis. Subjects and methods: This study included 64 patients with NHL and 30 healthy controls. Enzyme-linked immunosorbent assay (ELISA) was performed to determine serum levels of ANA. Results: There were significant differences in the serum ANA between NHL patients and controls (P<0.001). ANA positivity was detected in 19 NHL patients (29.6%). Positive ANA levels were observed in 17 patients in relapse of 19 (89.4%). No significant association was found between serum ANA levels and various clinicopathological and hematological features. There was a significant association between ANA levels and leukocyte common antigen (LCA) (P=0.010). ROC curve was applied to assess the diagnosis of relapse in NHL with cutoff >0.8 (AUC: 0.876). Conclusion: Our data argue that positive ANA levels can be useful for diagnosis of relapse in NHL patients.